Last Updated : April 28, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort ascending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Cystadrops | cysteamine | Corneal cystine crystal deposits | Reimburse with clinical criteria and/or conditions | Complete | ||
Cyramza | Ramucirumab | Metastatic Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Cyramza | Ramucirumab | Cancelled | ||||
Cymbalta | Duloxetine hydrochloride | Pain, Neuropathic, Diabetic | List with clinical criteria and/or conditions | Complete | ||
Cymbalta | Duloxetine hydrochloride | Depressive, Major Disorder (MDD) | Do not list | Complete | ||
Cuvposa | glycopyrrolate | chronic severe drooling, neurologic (pediatric) | Do not reimburse | Complete | ||
Cubicin | Daptomycin | Skin and skin structure infections & bacteremia | Do not list | Complete | ||
Crysvita | burosumab | Treatment of X-Linked Hypophosphatemia | Active | |||
Crysvita | burosumab | Treatment of X-Linked Hypophosphatemia | Reimburse with clinical criteria and/or conditions | Complete | ||
Cresemba | isavuconazole | Treatment of invasive aspergillosis and mucormycosis | Reimburse with clinical criteria and/or conditions | Complete |